First bDMARD failure and retention characteristics of the second bDMARD
| Second bDMARD | ||||||
|---|---|---|---|---|---|---|
| TNFi | Abatacept | |||||
| First bDMARD Failed | Failure type | All | Failure type | All | ||
| Primary | Secondary | Primary | Secondary | |||
| TNF inhibitor, n, % | 41, 25.5% | 120, 74.5% | 161, 100% | 17, 19.1% | 72, 80.9% | 89, 100% |
| Other mode of action | 6, 18.2% | 27, 81.8% | 33, 100% | 0, 0% | 3, 100% | 3, 100% |
| Total | 47, 24.2% | 147, 75.8% | 194, 100% | 17, 18.5% | 75, 81.5% | 92, 100% |
| Second bDMARD Retention Probability at1: | ||||||
| 6 Months | 64.68% (3.45%) | 83.51% (3.89%) | ||||
| 12 Months | 50.54% (3.61%) | 76.73% (4.45%) | ||||
| 24 Months | 39.77% (3.59%) | 59.97% (5.29%) | ||||
| 60 Months | 22.26% (3.53%) | 36.95% (6.17%) | ||||
| 96 Months | 13.22% (3.62%) | 30.66% (6.61%) | ||||
| Biologic Retention Time (years) | ||||||
| Mean, mean (SE) | 2.71 (0.25) | 3.33 (0.26) | ||||
| Lower Quartile (95% CI) | 0.36 (0.28–0.44) | 1.02 (0.49–1.29) | ||||
| Median (95% CI) | 1.08 (0.71–1.60) | 3.17 (1.92–4.78) | ||||
| Upper Quartile (95% CI) | 4.26 (3.25–6.64) | ++ (5.24-++) | ||||
1% survival (standard error of % survival).